Nonhomologous end joining key factor XLF enhances both 5-florouracil and oxaliplatin resistance in colorectal cancer

Liu Z, Miao Yu, Fei B, Jun Sun, Dawei WangSHILAP 2019

Abstract

Zhuo Liu,1 Miao Yu,1 Bingyuan Fei,1 Jing Sun,2 Dongxin Wang3 1Department of Gastrointestinal Colorectal and Anal Surgery, China–Japan Union Hospital of Jilin University, Changchun, Jilin 130021, China; 2Department of Biochemistry and Molecular Medicine, The George Washington University, Washington, DC 20052, USA; 3Department of Anesthesiology, Jilin Cancer Hospital, Changchun, Jilin 130021, China Background: Colorectal cancer (CRC) is the third commonly diagnosed cancer with a high risk of death. After curative surgery, 40% of patients will have metastases or develop recurrence. Therefore, chemotherapy is significantly responsible as the major therapy method. However, chemoresistance is found in almost all metastatic patients and remains a critical obstacle to curing CRC.Materials and methods: Cell viability is analyzed by sulforhodamine B staining assay. The nonhomologous end joining (NHEJ) repair ability of each cell line was determined by NHEJ reporter assay. mRNA expression levels of NHEJ factors are detected by real-time quantitative polymerase chain reaction. The protein expression levels were observed by western blot assay.Results: Our study found that 5-florouracil (5-Fu) and oxaliplatin (OXA)-resistant HCT116 and LS174T cells showed upregulated efficiency of DNA double-strand repair pathway NHEJ. We then identified that the NHEJ key factor XLF is responsible for the chemoresistance and XLF deficiency sensitizes CRC cells to 5-Fu and OXA significantly.Conclusion: Our research first demonstrates that the NHEJ pathway, especially its key factor XLF, significantly contributes to chemoresistance in CRC. Keywords: XLF, nonhomologous end joining, 5-florouracil, oxaliplatin, chemoresistance, colorectal cancer\n 
BibTeX
@inproceedings{z2019nonhomologous,
  author = {Liu Z and Miao Yu and Fei B and Jun Sun and Dawei Wang},
  title = {{Nonhomologous end joining key factor XLF enhances both 5-florouracil and oxaliplatin resistance in colorectal cancer}},
  booktitle = {SHILAP},
  year = {2019},
}

Loading related content...

Figure